For research and educational purposes only. Not intended for human consumption.
Bioglutide
Well Researched- •Oral quadruple agonist (no injections)
- •13.8% weight loss in Phase 2
- •Muscle-sparing weight loss unique
NA-931 | Quadruple IGF-1/GLP-1/GIP/Glucagon Agonist
Overview
What is Bioglutide?
Bioglutide (NA-931) is a first-in-class oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed up to 13.8% body weight reduction in 13 weeks while preserving muscle mass - a significant advantage over existing GLP-1 therapies. Currently in Phase 2b/3 trials.
Key Benefits
Oral administration (no injections), muscle-sparing weight loss (72% achieved ≥12% weight loss), once-daily dosing, milder GI side effects than injectable GLP-1s, quadruple receptor activation.
Mechanism of Action
NA-931 is a lipophilic small molecule that crosses the BBB and simultaneously activates IGF-1 (muscle preservation), GLP-1 (appetite suppression), GIP (glucose metabolism), and glucagon (energy expenditure) receptors.
Molecular Information
Pharmacokinetics
Research Indications
Obesity Management
13.8% weight reduction at 150mg in 13 weeks (Phase 2).
Muscle Preservation
No muscle loss observed - unique vs existing GLP-1s.
Visceral Fat
46% liver fat reduction in preclinical data.
Research Protocols
Disclaimer: Investigational drug - not yet FDA approved. In Phase 2b/3 clinical trials.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Starting Dose | 50mg | Once daily | Oral |
| Standard Dose | 100mg | Once daily | Oral |
| Maximum Clinical Dose | 150mg | Once daily | Oral |
Timing: Can be taken any time with or without food. No fasting required (unlike oral glp1-s).
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Oral capsule - no reconstitution needed
Take once daily with water
Can be taken with or without food
Store at room temperature or refrigerated
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Verified research source
From reputable suppliers with COA.
Limited availability
Investigational - limited outside clinical trials.
Unknown source
Never use from unverified sources.
What to Expect
- •Week 1-2: Mild appetite reduction, minimal GI effects
- •Week 2-4: Noticeable appetite suppression, early weight loss
- •Week 4-8: Steady weight loss (1-2+ lbs/week)
- •Week 8-13: 10-14% total weight reduction possible
Side Effects & Safety
Side Effects
- •Investigational drug - not FDA approved
- •Mild nausea (7.3%), diarrhea (6.3-8.1%)
- •83% of GI events rated mild or insignificant
- •No serious drug-related events in Phase 2
- •MTC risk (GLP-1 class concern)
When to Stop
- •Severe GI symptoms
- •Signs of pancreatitis
- •Any serious adverse effects
References
1 StudiesPhase 2 Clinical Trial (2024)
Human | 125 patients | 13 weeks | 13.8% weight loss at 150mg
72% achieved ≥12% weight loss vs 2% placebo. No muscle loss observed.
Quick Start Guide
Research Disclaimer
Bioglutide is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Bioglutide must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Bioglutide for any purpose. Consult qualified professionals for any research applications.